首页> 美国卫生研究院文献>Integrative Cancer Therapies >Effects of Shen Cao Granules on Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancer Patients: A Randomized Controlled Trial
【2h】

Effects of Shen Cao Granules on Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancer Patients: A Randomized Controlled Trial

机译:参草冲剂对胃肠道肿瘤患者化疗致血小板减少的影响:一项随机对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: To observe clinical effects of Shen Cao granules on thrombocytopenia in patients with gastrointestinal cancer undergoing chemotherapy. >Patients and Methods: Patients under a FOLFIRI chemotherapy regimen (n = 92) were randomly divided into study and control groups (n = 46 for each group) and were given 10 g of Shen Cao granules and a placebo, respectively, once daily on chemotherapy treatment days. Platelet counts were measured every other day and any adverse reaction recorded during the study and at follow-up. >Results: The incidence of thrombocytopenia (grades II-IV) in the study group was significantly decreased, and the length of hospitalization significantly reduced compared with the control group (11.21 ± 2.46 vs 15.34 ± 3.68 days, P < .05). The minimum numbers of post-chemotherapy platelets and the values of platelet counts 21 days after chemotherapy were significantly increased ([100.65 ± 63.16] × 109/L vs [60.21 ±37.22] × 109/L, P < .05; [267.81 ± 81.32] × 109/L vs [146.42 ± 70.54] × 109/L, P < .001), and the duration of thrombocytopenia and treatment with recombinant human interleukin-11 was significantly decreased in the Shen Cao treatment compared with the control group. No serious adverse events were observed. >Conclusions: Shen Cao granules were effective in decreasing chemotherapy-induced thrombocytopenia, shortened the duration of thrombocytopenia, and reduced the length of hospital stay and costs.
机译:>背景:观察参草冲剂对消化道消化道癌症患者血小板减少的临床效果。 >患者和方法:将接受FOLFIRI化疗的患者(n = 92)随机分为研究组和对照组(每组n = 46),并给予10 g的神草颗粒和安慰剂分别在化疗治疗日每天一次。每隔一天测量一次血小板计数,并在研究期间和随访时记录任何不良反应。 >结果:与对照组相比,研究组的血小板减少症(II-IV级)的发生率显着降低,住院时间明显减少(11.21±2.46 vs 15.34±3.68天,P <.05)。化疗后21天的最小血小板数和血小板计数值显着增加([100.65±63.16]×10 9 / L与[60.21±37.22]×10 9 / L,P <.05; [267.81±81.32]×10 9 / L与[146.42±70.54]×10 9 / L,P <.001),并且与对照组相比,深草疗法的血小板减少症和重组人白介素11治疗的持续时间显着减少。没有观察到严重的不良事件。 >结论:参草颗粒可有效减少化疗引起的血小板减少症,缩短血小板减少症的持续时间,并减少住院时间和费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号